Share This Author
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Concern about cardiovascular safety of sulphonylureas has largely dissipated with generally reassuring results from clinical trials, including the UKPDS, and the insulin-sensitising thiazolidinedione class of antidiabetic agents has potentially advantageous effects on multiple components of the metabolic syndrome.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart Failure than placebo but was associated with adverse events.
Metformin in patients with type 2 diabetes and kidney disease: a systematic review.
Available evidence supports cautious expansion of metformin use in patients with mild to moderate chronic kidney disease, as defined by estimated glomerular filtration rate, with appropriate dosage reductions and careful follow-up of kidney function.
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
- C. Bailey, J. Gross, D. Hennicken, N. Iqbal, T. Mansfield, J. List
- MedicineBMC Medicine
- 20 February 2013
Dapagliflozin added to meetformin for 102 weeks enabled sustained reductions in HbA1c, FPG, and weight without increased risk of hypoglycemia in patients with type 2 diabetes who were inadequately controlled on metformin alone.
Biguanides and NIDDM
- C. Bailey
- MedicineDiabetes Care
- 1 June 1992
Because metformin does not cause clinical hypoglycemia, it is actually an antihyperglycemic drug that helps combat hypertriglyceridemia, and it has been ascribed some vasoprotective properties.
Metformin: historical overview
- C. Bailey
- 1 September 2017
Sixty years after its introduction in diabetes treatment, metformin has become the most prescribed glucose-lowering medicine worldwide with the potential for further therapeutic applications.
Insulin‐like effect of pinitol
The data support the view that D‐pinitol can exert an insulin‐like effect to improve glycaemic control in hypoinsulinaemic STZ‐diabetic mice.
Traditional Plant Medicines as Treatments for Diabetes
Traditional treatments for diabetes mellitus may provide valuable clues for the development of new oral hypoglycemic agents and simple dietary adjuncts.
Accumulation of metformin by tissues of the normal and diabetic mouse.
Tissue accumulation of the antihyperglycaemic agent metformin (dimethylbiguanide) was examined after oral administration to the normal and streptozotocin (STZ) diabetic mouse, and retention of metform in tissues of the small intestine may represent a deep compartment for the drug.